<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35538484</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1476-4598</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>21</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>10</Day>
            </PubDate>
          </JournalIssue>
          <Title>Molecular cancer</Title>
          <ISOAbbreviation>Mol Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Liquid biopsies to occult brain metastasis.</ArticleTitle>
        <Pagination>
          <StartPage>113</StartPage>
          <MedlinePgn>113</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">113</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12943-022-01577-x</ELocationID>
        <Abstract>
          <AbstractText>Brain metastasis (BrM) is a major problem associated with cancer-related mortality, and currently, no specific biomarkers are available in clinical settings for early detection. Liquid biopsy is widely accepted as a non-invasive method for diagnosing cancer and other diseases. We have reviewed the evidence that shows how the molecular alterations are involved in BrM, majorly from breast cancer (BC), lung cancer (LC), and melanoma, with an inception in how they can be employed for biomarker development. We discussed genetic and epigenetic changes that influence cancer cells to breach the blood-brain barrier (BBB) and help to establish metastatic lesions in the uniquely distinct brain microenvironment. Keeping abreast with the recent breakthroughs in the context of various biomolecules detections and identifications, the circulating tumor cells (CTC), cell-free nucleotides, non-coding RNAs, secretory proteins, and metabolites can be pursued in human body fluids such as blood, serum, cerebrospinal fluid (CSF), and urine to obtain potential candidates for biomarker development. The liquid biopsy-based biomarkers can overlay with current imaging techniques to amplify the signal viable for improving the early detection and treatments of occult BrM.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Rehman</LastName>
            <ForeName>Asad Ur</ForeName>
            <Initials>AU</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, 68108, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Khan</LastName>
            <ForeName>Parvez</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, 68108, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Maurya</LastName>
            <ForeName>Shailendra Kumar</ForeName>
            <Initials>SK</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, 68108, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Siddiqui</LastName>
            <ForeName>Jawed A</ForeName>
            <Initials>JA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, 68108, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, 68108, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Santamaria-Barria</LastName>
            <ForeName>Juan A</ForeName>
            <Initials>JA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University of Nebraska Medical Center, Omaha, NE, 68108, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Batra</LastName>
            <ForeName>Surinder K</ForeName>
            <Initials>SK</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, 68108, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, 68108, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE-68198, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nasser</LastName>
            <ForeName>Mohd Wasim</ForeName>
            <Initials>MW</Initials>
            <Identifier Source="ORCID">0000-0003-2070-4972</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, 68108, USA. wasim.nasser@unmc.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, 68108, USA. wasim.nasser@unmc.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01CA218545</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01CA241752</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P01 CA217798</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Mol Cancer</MedlineTA>
        <NlmUniqueID>101147698</NlmUniqueID>
        <ISSNLinking>1476-4598</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001932" MajorTopicYN="Y">Brain Neoplasms</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="Y">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000073890" MajorTopicYN="N">Liquid Biopsy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009360" MajorTopicYN="Y">Neoplastic Cells, Circulating</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Brain microenvironment</Keyword>
        <Keyword MajorTopicYN="N">CTCs</Keyword>
        <Keyword MajorTopicYN="N">Cancer diagnostics</Keyword>
        <Keyword MajorTopicYN="N">Cell-free DNA</Keyword>
        <Keyword MajorTopicYN="N">Exosomes</Keyword>
        <Keyword MajorTopicYN="N">microRNA</Keyword>
      </KeywordList>
      <CoiStatement>SKB is co-founder of Sanguine Diagnostics and Therapeutics, Inc. Other authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>10</Day>
          <Hour>23</Hour>
          <Minute>38</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35538484</ArticleId>
        <ArticleId IdType="pmc">PMC9088117</ArticleId>
        <ArticleId IdType="doi">10.1186/s12943-022-01577-x</ArticleId>
        <ArticleId IdType="pii">10.1186/s12943-022-01577-x</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Dimenstein IB. Grossing biopsies: an introduction to general principles and techniques. Ann Diagn Pathol. 2009;13:106–113. doi: 10.1016/j.anndiagpath.2008.12.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.anndiagpath.2008.12.010</ArticleId>
            <ArticleId IdType="pubmed">19302959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang CC, Huang KT, Chang HC, Tseng CC, Lai CH, Lan J, et al. Comprehensive analysis of PD-L1 in non-small cell lung cancer with emphasis on survival benefit, impact of driver mutation and histological types, and archival tissue. Thorac Cancer. 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Zarogoulidis P, Gaga M, Huang H, Darwiche K, Rapti A, Hohenforst-Schmidt W. Tissue is the issue and tissue competition. Re-biopsy for mutation T790: where and why? Clin Transl Med. 2017;6(6).</Citation>
        </Reference>
        <Reference>
          <Citation>Hofman P. The challenges of evaluating predictive biomarkers using small biopsy tissue samples and liquid biopsies from non-small cell lung cancer patients. J Thorac Dis. 2019;11:S57–S64. doi: 10.21037/jtd.2018.11.85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.21037/jtd.2018.11.85</ArticleId>
            <ArticleId IdType="pmc">PMC6353749</ArticleId>
            <ArticleId IdType="pubmed">30775028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodriguez J, Avila J, Rolfo C, Ruiz-Patino A, Russo A, Ricaurte L, Ordonez-Reyes C, Arrieta O, Zatarain-Barron ZL, Recondo G, Cardona AF. When tissue is an issue the liquid biopsy is nonissue: a review. Oncol Ther. 2021;9:89–110. doi: 10.1007/s40487-021-00144-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40487-021-00144-6</ArticleId>
            <ArticleId IdType="pmc">PMC8140006</ArticleId>
            <ArticleId IdType="pubmed">33689160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vendramin R, Litchfield K, Swanton C. Cancer evolution: Darwin and beyond. EMBO J. 2021;40:e108389. doi: 10.15252/embj.2021108389.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15252/embj.2021108389</ArticleId>
            <ArticleId IdType="pmc">PMC8441388</ArticleId>
            <ArticleId IdType="pubmed">34459009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwak EL, Ahronian LG, Siravegna G, Mussolin B, Borger DR, Godfrey JT, Jessop NA, Clark JW, Blaszkowsky LS, Ryan DP, et al.  Molecular heterogeneity and receptor Coamplification drive resistance to targeted therapy in MET-amplified Esophagogastric Cancer. Cancer Discov. 2015;5:1271–1281. doi: 10.1158/2159-8290.CD-15-0748.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-15-0748</ArticleId>
            <ArticleId IdType="pmc">PMC4670804</ArticleId>
            <ArticleId IdType="pubmed">26432108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan P, Grundy L, Makary P, Eng KH, Ramsay G, Bekheit M. The value of liquid biopsy in the diagnosis and staging of hepatocellular carcinoma: a systematic review. Transl Gastroenterol Hepatol. 2021;6:54. doi: 10.21037/tgh.2020.01.11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.21037/tgh.2020.01.11</ArticleId>
            <ArticleId IdType="pmc">PMC8573369</ArticleId>
            <ArticleId IdType="pubmed">34805576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang M, Jin S, Han J, Li T, Shi J, Zhong Q, Li W, Tang W, Huang Q, Zong H. Detection and clinical significance of circulating tumor cells in colorectal cancer. Biomark Res. 2021;9:85. doi: 10.1186/s40364-021-00326-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40364-021-00326-4</ArticleId>
            <ArticleId IdType="pmc">PMC8605607</ArticleId>
            <ArticleId IdType="pubmed">34798902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mattox AK, Bettegowda C, Zhou S, Papadopoulos N, Kinzler KW, Vogelstein B. Applications of liquid biopsies for cancer. Sci Transl Med. 2019:11.</Citation>
        </Reference>
        <Reference>
          <Citation>Hanna TP, King WD, Thibodeau S, Jalink M, Paulin GA, Harvey-Jones E, O'Sullivan DE, Booth CM, Sullivan R, Aggarwal A. Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ. 2020;371:m4087. doi: 10.1136/bmj.m4087.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.m4087</ArticleId>
            <ArticleId IdType="pmc">PMC7610021</ArticleId>
            <ArticleId IdType="pubmed">33148535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamza B, Miller AB, Meier L, Stockslager M, Ng SR, King EM, Lin L, DeGouveia KL, Mulugeta N, Calistri NL, et al.  Measuring kinetics and metastatic propensity of CTCs by blood exchange between mice. Nat Commun. 2021;12:5680. doi: 10.1038/s41467-021-25917-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-021-25917-5</ArticleId>
            <ArticleId IdType="pmc">PMC8479082</ArticleId>
            <ArticleId IdType="pubmed">34584084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Freitas C, Sousa C, Machado F, Serino M, Santos V, Cruz-Martins N, Teixeira A, Cunha A, Pereira T, Oliveira HP, et al.  The role of liquid biopsy in early diagnosis of lung Cancer. Front Oncol. 2021;11:634316. doi: 10.3389/fonc.2021.634316.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2021.634316</ArticleId>
            <ArticleId IdType="pmc">PMC8085425</ArticleId>
            <ArticleId IdType="pubmed">33937034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harangus A, Berindan-Neagoe I, Todea DA, Simon I, Simon M. Noncoding RNAs and liquid biopsy in lung Cancer. A Literature Review Diagnostics (Basel). 2019;9.</Citation>
        </Reference>
        <Reference>
          <Citation>Kalogianni DP. Nanotechnology in emerging liquid biopsy applications. Nano Converg. 2021;8:13. doi: 10.1186/s40580-021-00263-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40580-021-00263-w</ArticleId>
            <ArticleId IdType="pmc">PMC8088419</ArticleId>
            <ArticleId IdType="pubmed">33934252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Derman BA, Stefka AT, Jiang K, McIver A, Kubicki T, Jasielec JK, Jakubowiak AJ. Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation. Blood Cancer J. 2021;11:19. doi: 10.1038/s41408-021-00418-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41408-021-00418-2</ArticleId>
            <ArticleId IdType="pmc">PMC7873068</ArticleId>
            <ArticleId IdType="pubmed">33563912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riggio AI, Varley KE, Welm AL. The lingering mysteries of metastatic recurrence in breast cancer. Br J Cancer. 2021;124:13–26. doi: 10.1038/s41416-020-01161-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41416-020-01161-4</ArticleId>
            <ArticleId IdType="pmc">PMC7782773</ArticleId>
            <ArticleId IdType="pubmed">33239679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, et al.  Corrigendum: phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2018;554:264. doi: 10.1038/nature25161.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature25161</ArticleId>
            <ArticleId IdType="pubmed">29258292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morgan AJ, Giannoudis A, Palmieri C. The genomic landscape of breast cancer brain metastases: a systematic review. Lancet Oncol. 2021;22:e7–e17. doi: 10.1016/S1470-2045(20)30556-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(20)30556-8</ArticleId>
            <ArticleId IdType="pubmed">33387511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reiter JG, Baretti M, Gerold JM, Makohon-Moore AP, Daud A, Iacobuzio-Donahue CA, Azad NS, Kinzler KW, Nowak MA, Vogelstein B. An analysis of genetic heterogeneity in untreated cancers. Nat Rev Cancer. 2019;19:639–650. doi: 10.1038/s41568-019-0185-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41568-019-0185-x</ArticleId>
            <ArticleId IdType="pmc">PMC6816333</ArticleId>
            <ArticleId IdType="pubmed">31455892</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miarka L, Valiente M. Animal models of brain metastasis. Neurooncol Adv. 2021;3:v144–v156.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8633729</ArticleId>
            <ArticleId IdType="pubmed">34859241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Valiente M, Van Swearingen AED, Anders CK, Bairoch A, Boire A, Bos PD, Cittelly DM, Erez N, Ferraro GB, Fukumura D, et al.  Brain metastasis cell lines panel: a public resource of Organotropic cell lines. Cancer Res. 2020;80:4314–4323. doi: 10.1158/0008-5472.CAN-20-0291.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-20-0291</ArticleId>
            <ArticleId IdType="pmc">PMC7572582</ArticleId>
            <ArticleId IdType="pubmed">32641416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Z, Wang Y, Kabraji S, Xie S, Pan P, Liu Z, Ni J, Zhao JJ. Improving orthotopic mouse models of patient-derived breast cancer brain metastases by a modified intracarotid injection method. Sci Rep. 2019;9:622. doi: 10.1038/s41598-018-36874-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-018-36874-3</ArticleId>
            <ArticleId IdType="pmc">PMC6346002</ArticleId>
            <ArticleId IdType="pubmed">30679540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang C, Lowery FJ, Yu D. Intracarotid Cancer cell injection to produce mouse models of brain metastasis. J Vis Exp. 2017.</Citation>
        </Reference>
        <Reference>
          <Citation>Xing F, Liu Y, Sharma S, Wu K, Chan MD, Lo HW, Carpenter RL, Metheny-Barlow LJ, Zhou X, Qasem SA, et al.  Activation of the c-met pathway mobilizes an inflammatory network in the brain microenvironment to promote brain metastasis of breast Cancer. Cancer Res. 2016;76:4970–4980. doi: 10.1158/0008-5472.CAN-15-3541.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-15-3541</ArticleId>
            <ArticleId IdType="pmc">PMC5010459</ArticleId>
            <ArticleId IdType="pubmed">27364556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gautam SK, Kanchan RK, Siddiqui JA, Maurya SK, Rauth S, Perumal N, et al. Blocking c-MET/ERBB1 Axis prevents brain metastasis in ERBB2+ breast Cancer. Cancers (Basel). 2020;12.</Citation>
        </Reference>
        <Reference>
          <Citation>Oliver CR, Westerhof TM, Castro MG, Merajver SD. Quantifying the brain metastatic tumor Micro-environment using an organ-on-a Chip 3D model, Machine Learning, and Confocal Tomography. J Vis Exp. 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Kwapisz D. The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer? Ann Transl Med. 2017;5(46).</Citation>
        </Reference>
        <Reference>
          <Citation>Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, et al.  Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165:35–44. doi: 10.1016/j.cell.2016.02.065.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2016.02.065</ArticleId>
            <ArticleId IdType="pmc">PMC4808437</ArticleId>
            <ArticleId IdType="pubmed">26997480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20:5064–5074. doi: 10.1158/1078-0432.CCR-13-3271.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-13-3271</ArticleId>
            <ArticleId IdType="pmc">PMC4185001</ArticleId>
            <ArticleId IdType="pubmed">24714771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lennon AM, Buchanan AH, Kinde I, Warren A, Honushefsky A, Cohain AT, et al. Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science. 2020;369.</Citation>
        </Reference>
        <Reference>
          <Citation>Woo D, Yu M. Circulating tumor cells as "liquid biopsies" to understand cancer metastasis. Transl Res. 2018;201:128–135. doi: 10.1016/j.trsl.2018.07.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.trsl.2018.07.003</ArticleId>
            <ArticleId IdType="pmc">PMC6177282</ArticleId>
            <ArticleId IdType="pubmed">30075099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boral D, Vishnoi M, Liu HN, Yin W, Sprouse ML, Scamardo A, Hong DS, Tan TZ, Thiery JP, Chang JC, Marchetti D. Molecular characterization of breast cancer CTCs associated with brain metastasis. Nat Commun. 2017;8:196. doi: 10.1038/s41467-017-00196-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-017-00196-1</ArticleId>
            <ArticleId IdType="pmc">PMC5543046</ArticleId>
            <ArticleId IdType="pubmed">28775303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aljohani HM, Aittaleb M, Furgason JM, Amaya P, Deeb A, Chalmers JJ, Bahassi EM. Genetic mutations associated with lung cancer metastasis to the brain. Mutagenesis. 2018;33:137–145. doi: 10.1093/mutage/gey003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/mutage/gey003</ArticleId>
            <ArticleId IdType="pmc">PMC6454536</ArticleId>
            <ArticleId IdType="pubmed">29474635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klotz R, Thomas A, Teng T, Han SM, Iriondo O, Li L, Restrepo-Vassalli S, Wang A, Izadian N, MacKay M, et al.  Circulating tumor cells exhibit metastatic tropism and reveal brain metastasis drivers. Cancer Discov. 2020;10:86–103. doi: 10.1158/2159-8290.CD-19-0384.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-19-0384</ArticleId>
            <ArticleId IdType="pmc">PMC6954305</ArticleId>
            <ArticleId IdType="pubmed">31601552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L, Ridgway LD, Wetzel MD, Ngo J, Yin W, Kumar D, et al. The identification and characterization of breast cancer CTCs competent for brain metastasis. Sci Transl Med. 2013;5:180ra148.</Citation>
        </Reference>
        <Reference>
          <Citation>Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, Minn AJ, van de Vijver MJ, Gerald WL, Foekens JA, Massague J. Genes that mediate breast cancer metastasis to the brain. Nature. 2009;459:1005–1009. doi: 10.1038/nature08021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature08021</ArticleId>
            <ArticleId IdType="pmc">PMC2698953</ArticleId>
            <ArticleId IdType="pubmed">19421193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang G, Shi L, Ye Y, Shi H, Zeng L, Tiwary S, Huse JT, Huo L, Ma L, Ma Y, et al.  YTHDF3 induces the translation of m (6) A-enriched gene transcripts to promote breast Cancer brain metastasis. Cancer Cell. 2020;38(857-871):e857. doi: 10.1016/j.ccell.2020.10.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2020.10.004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cordone I, Masi S, Summa V, Carosi M, Vidiri A, Fabi A, Pasquale A, Conti L, Rosito I, Carapella CM, et al.  Overexpression of syndecan-1, MUC-1, and putative stem cell markers in breast cancer leptomeningeal metastasis: a cerebrospinal fluid flow cytometry study. Breast Cancer Res. 2017;19:46. doi: 10.1186/s13058-017-0827-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13058-017-0827-4</ArticleId>
            <ArticleId IdType="pmc">PMC5387324</ArticleId>
            <ArticleId IdType="pubmed">28399903</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim BG, Jang JH, Kim JW, Shin SH, Jeong BH, Lee K, et al. Clinical utility of plasma cell-free DNA EGFR mutation analysis in treatment-naive stage IV non-small cell lung Cancer patients. J Clin Med. 2022;11.</Citation>
        </Reference>
        <Reference>
          <Citation>Liang J, Zhao W, Lu C, Liu D, Li P, Ye X, Zhao Y, Zhang J, Yang D. Next-generation sequencing analysis of ctDNA for the detection of glioma and metastatic brain tumors in adults. Front Neurol. 2020;11:544. doi: 10.3389/fneur.2020.00544.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fneur.2020.00544</ArticleId>
            <ArticleId IdType="pmc">PMC7473301</ArticleId>
            <ArticleId IdType="pubmed">32973641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pangeni RP, Olivaries I, Huen D, Buzatto VC, Dawson TP, Ashton KM, Davis C, Brodbelt AR, Jenkinson MD, Bieche I, et al.  Genome-wide methylation analyses identifies non-coding RNA genes dysregulated in breast tumours that metastasise to the brain. Sci Rep. 2022;12:1102. doi: 10.1038/s41598-022-05050-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-022-05050-z</ArticleId>
            <ArticleId IdType="pmc">PMC8776809</ArticleId>
            <ArticleId IdType="pubmed">35058523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan X, Wei Q, Komaki R, Liu Z, Yang J, Tucker SL, Xu T, Heymach JV, Lu C, Cox JD, Liao Z. TGFbeta1 polymorphisms predict distant metastasis-free survival in patients with inoperable non-small-cell lung Cancer after definitive radiotherapy. PLoS One. 2013;8:e65659. doi: 10.1371/journal.pone.0065659.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0065659</ArticleId>
            <ArticleId IdType="pmc">PMC3686751</ArticleId>
            <ArticleId IdType="pubmed">23840350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma C, Yang X, Xing W, Yu H, Si T, Guo Z. Detection of circulating tumor DNA from non-small cell lung cancer brain metastasis in cerebrospinal fluid samples. Thorac Cancer. 2020;11:588–593. doi: 10.1111/1759-7714.13300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/1759-7714.13300</ArticleId>
            <ArticleId IdType="pmc">PMC7049513</ArticleId>
            <ArticleId IdType="pubmed">31944608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Mattos-Arruda L, Mayor R, Ng CKY, Weigelt B, Martinez-Ricarte F, Torrejon D, Oliveira M, Arias A, Raventos C, Tang J, et al.  Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun. 2015;6:8839. doi: 10.1038/ncomms9839.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms9839</ArticleId>
            <ArticleId IdType="pmc">PMC5426516</ArticleId>
            <ArticleId IdType="pubmed">26554728</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ascierto PA, Minor D, Ribas A, Lebbe C, O'Hagan A, Arya N, Guckert M, Schadendorf D, Kefford RF, Grob JJ, et al.  Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol. 2013;31:3205–3211. doi: 10.1200/JCO.2013.49.8691.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2013.49.8691</ArticleId>
            <ArticleId IdType="pubmed">23918947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei S, Liu W, Xu M, Qin H, Liu C, Zhang R, et al. Cathepsin F and Fibulin-1 as novel diagnostic biomarkers for brain metastasis of non-small cell lung cancer. Br J Cancer. 2022.</Citation>
        </Reference>
        <Reference>
          <Citation>Yuksel U, Ogden M, Ozdemir A, Kisa U, Bakar B. Predictive diagnostic and/or prognostic biomarkers obtained from routine blood biochemistry in patients with solitary intracranial tumor. J Med Biochem. 2021;40:67–73. doi: 10.5937/jomb0-24722.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5937/jomb0-24722</ArticleId>
            <ArticleId IdType="pmc">PMC7857846</ArticleId>
            <ArticleId IdType="pubmed">33584142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jin Y, Kang Y, Wang M, Wu B, Su B, Yin H, Tang Y, Li Q, Wei W, Mei Q, et al.  Targeting polarized phenotype of microglia via IL6/JAK2/STAT3 signaling to reduce NSCLC brain metastasis. Signal Transduct Target Ther. 2022;7:52. doi: 10.1038/s41392-022-00872-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41392-022-00872-9</ArticleId>
            <ArticleId IdType="pmc">PMC8864012</ArticleId>
            <ArticleId IdType="pubmed">35194016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pang X, Min J, Liu L, Liu Y, Ma N, Zhang H. S100B protein as a possible participant in the brain metastasis of NSCLC. Med Oncol. 2012;29:2626–2632. doi: 10.1007/s12032-012-0169-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12032-012-0169-0</ArticleId>
            <ArticleId IdType="pubmed">22286962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu W, Zhao J, Wei Y. Association between brain metastasis from lung cancer and the serum level of myelin basic protein. Exp Ther Med. 2015;9:1048–1050. doi: 10.3892/etm.2015.2195.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/etm.2015.2195</ArticleId>
            <ArticleId IdType="pmc">PMC4316904</ArticleId>
            <ArticleId IdType="pubmed">25667676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang YT, Jiang F, Guo L, Si MY, Jiao XY. The soluble VEGF receptor 1 and 2 expression in cerebral spinal fluid as an indicator for leukemia central nervous system metastasis. J Neuro-Oncol. 2013;112:329–338. doi: 10.1007/s11060-013-1066-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-013-1066-x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Darlix A, Hirtz C, Mollevi C, Ginestet N, Tiers L, Jacot W, Lehmann S. Serum glial fibrillary acidic protein is a predictor of brain metastases in patients with metastatic breast cancer. Int J Cancer. 2021;149:1605–1618. doi: 10.1002/ijc.33724.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.33724</ArticleId>
            <ArticleId IdType="pubmed">34196964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Darlix A, Hirtz C, Thezenas S, Maceski A, Gabelle A, Lopez-Crapez E, De Forges H, Firmin N, Guiu S, Jacot W, Lehmann S. The prognostic value of the tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases. BMC Cancer. 2019;19:110. doi: 10.1186/s12885-019-5287-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12885-019-5287-z</ArticleId>
            <ArticleId IdType="pmc">PMC6354387</ArticleId>
            <ArticleId IdType="pubmed">30700265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Winther-Larsen A, Hviid CVB, Meldgaard P, Sorensen BS, Sandfeld-Paulsen B. Neurofilament light chain as a biomarker for brain metastases, vol. 12. Cancers (Basel); 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Curtaz CJ, Schmitt C, Herbert SL, Feldheim J, Schlegel N, Gosselet F, Hagemann C, Roewer N, Meybohm P, Wockel A, Burek M. Serum-derived factors of breast cancer patients with brain metastases alter permeability of a human blood-brain barrier model. Fluids Barriers CNS. 2020;17:31. doi: 10.1186/s12987-020-00192-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12987-020-00192-6</ArticleId>
            <ArticleId IdType="pmc">PMC7178982</ArticleId>
            <ArticleId IdType="pubmed">32321535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen GY, Cheng JC, Chen YF, Yang JC, Hsu FM. Circulating Exosomal integrin beta3 is associated with intracranial failure and survival in lung Cancer patients receiving cranial irradiation for brain metastases: a prospective observational study. Cancers (Basel). 2021;13.</Citation>
        </Reference>
        <Reference>
          <Citation>Rodrigues G, Hoshino A, Kenific CM, Matei IR, Steiner L, Freitas D, Kim HS, Oxley PR, Scandariato I, Casanova-Salas I, et al.  Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis. Nat Cell Biol. 2019;21:1403–1412. doi: 10.1038/s41556-019-0404-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41556-019-0404-4</ArticleId>
            <ArticleId IdType="pmc">PMC7354005</ArticleId>
            <ArticleId IdType="pubmed">31685984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei L, Wang G, Yang C, Zhang Y, Chen Y, Zhong C, Li Q. MicroRNA-550a-3-5p controls the brain metastasis of lung cancer by directly targeting YAP1. Cancer Cell Int. 2021;21:491. doi: 10.1186/s12935-021-02197-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12935-021-02197-z</ArticleId>
            <ArticleId IdType="pmc">PMC8444378</ArticleId>
            <ArticleId IdType="pubmed">34530822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou W, Fong MY, Min Y, Somlo G, Liu L, Palomares MR, Yu Y, Chow A, O'Connor ST, Chin AR, et al.  Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell. 2014;25:501–515. doi: 10.1016/j.ccr.2014.03.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2014.03.007</ArticleId>
            <ArticleId IdType="pmc">PMC4016197</ArticleId>
            <ArticleId IdType="pubmed">24735924</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Im JH, Kim TH, Lee KY, Gwak HS, Lin W, Park JB, et al. Exploratory profiling of extracellular MicroRNAs in cerebrospinal fluid comparing leptomeningeal metastasis with other central nervous system tumor statuses. J Clin Med. 2021;10.</Citation>
        </Reference>
        <Reference>
          <Citation>Wong GL, Abu Jalboush S, Lo HW. Exosomal MicroRNAs and organotropism in breast Cancer metastasis, vol. 12. Cancers (Basel); 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Tominaga N, Kosaka N, Ono M, Katsuda T, Yoshioka Y, Tamura K, Lotvall J, Nakagama H, Ochiya T. Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood-brain barrier. Nat Commun. 2015;6:6716. doi: 10.1038/ncomms7716.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms7716</ArticleId>
            <ArticleId IdType="pmc">PMC4396394</ArticleId>
            <ArticleId IdType="pubmed">25828099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kanchan RK, Siddiqui JA, Mahapatra S, Batra SK, Nasser MW. microRNAs orchestrate pathophysiology of breast Cancer brain metastasis: advances in therapy. Mol Cancer. 2020;19:29. doi: 10.1186/s12943-020-1140-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12943-020-1140-x</ArticleId>
            <ArticleId IdType="pmc">PMC7023699</ArticleId>
            <ArticleId IdType="pubmed">32059676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J, Jing W, Jia W, Zhai X, Zhu H, Yu J. Downregulation of lncRNA XR_429159.1 linked to brain metastasis in patients with limited-stage small-cell lung Cancer. Front Oncol. 2021:11:603271.</Citation>
        </Reference>
        <Reference>
          <Citation>Lin D, Shen L, Luo M, Zhang K, Li J, Yang Q, Zhu F, Zhou D, Zheng S, Chen Y, Zhou J. Circulating tumor cells: biology and clinical significance. Signal Transduct Target Ther. 2021;6:404. doi: 10.1038/s41392-021-00817-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41392-021-00817-8</ArticleId>
            <ArticleId IdType="pmc">PMC8606574</ArticleId>
            <ArticleId IdType="pubmed">34803167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park SY, Nam JS. The force awakens: metastatic dormant cancer cells. Exp Mol Med. 2020;52:569–581. doi: 10.1038/s12276-020-0423-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s12276-020-0423-z</ArticleId>
            <ArticleId IdType="pmc">PMC7210927</ArticleId>
            <ArticleId IdType="pubmed">32300189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hosseini H, Obradovic MMS, Hoffmann M, Harper KL, Sosa MS, Werner-Klein M, Nanduri LK, Werno C, Ehrl C, Maneck M, et al.  Early dissemination seeds metastasis in breast cancer. Nature. 2016;540:552–558. doi: 10.1038/nature20785.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature20785</ArticleId>
            <ArticleId IdType="pmc">PMC5390864</ArticleId>
            <ArticleId IdType="pubmed">27974799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gruber IV, Hartkopf AD, Hahn M, Taran FA, Staebler A, Wallwiener D, Brucker SY, Hanke J, Fehm T. Relationship between Hematogenous tumor cell dissemination and cellular immunity in DCIS patients. Anticancer Res. 2016;36:2345–2351.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27127142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanger N, Effenberger KE, Riethdorf S, Van Haasteren V, Gauwerky J, Wiegratz I, Strebhardt K, Kaufmann M, Pantel K. Disseminated tumor cells in the bone marrow of patients with ductal carcinoma in situ. Int J Cancer. 2011;129:2522–2526. doi: 10.1002/ijc.25895.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.25895</ArticleId>
            <ArticleId IdType="pubmed">21207426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klein CA. Parallel progression of primary tumours and metastases. Nat Rev Cancer. 2009;9:302–312. doi: 10.1038/nrc2627.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc2627</ArticleId>
            <ArticleId IdType="pubmed">19308069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castro-Giner F, Aceto N. Tracking cancer progression: from circulating tumor cells to metastasis. Genome Med. 2020;12:31. doi: 10.1186/s13073-020-00728-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13073-020-00728-3</ArticleId>
            <ArticleId IdType="pmc">PMC7082968</ArticleId>
            <ArticleId IdType="pubmed">32192534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carter L, Rothwell DG, Mesquita B, Smowton C, Leong HS, Fernandez-Gutierrez F, Li Y, Burt DJ, Antonello J, Morrow CJ, et al.  Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer. Nat Med. 2017;23:114–119. doi: 10.1038/nm.4239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.4239</ArticleId>
            <ArticleId IdType="pubmed">27869802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malani R, Fleisher M, Kumthekar P, Lin X, Omuro A, Groves MD, Lin NU, Melisko M, Lassman AB, Jeyapalan S, et al.  Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer. J Neuro-Oncol. 2020;148:599–606. doi: 10.1007/s11060-020-03555-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-020-03555-z</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruan H, Zhou Y, Shen J, Zhai Y, Xu Y, Pi L, Huang R, Chen K, Li X, Ma W, et al.  Circulating tumor cell characterization of lung cancer brain metastases in the cerebrospinal fluid through single-cell transcriptome analysis. Clin Transl Med. 2020;10:e246. doi: 10.1002/ctm2.246.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ctm2.246</ArticleId>
            <ArticleId IdType="pmc">PMC7737787</ArticleId>
            <ArticleId IdType="pubmed">33377642</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sevenich L, Bowman RL, Mason SD, Quail DF, Rapaport F, Elie BT, Brogi E, Brastianos PK, Hahn WC, Holsinger LJ, et al.  Analysis of tumour- and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin S. Nat Cell Biol. 2014;16:876–888. doi: 10.1038/ncb3011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb3011</ArticleId>
            <ArticleId IdType="pmc">PMC4249762</ArticleId>
            <ArticleId IdType="pubmed">25086747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilkinson RDA, Burden RE, McDowell SH, McArt DG, McQuaid S, Bingham V, Williams R, Cox OT, O'Connor R, McCabe N, et al.  A novel role for Cathepsin S as a potential biomarker in triple negative breast Cancer. J Oncol. 2019;2019:3980273. doi: 10.1155/2019/3980273.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2019/3980273</ArticleId>
            <ArticleId IdType="pmc">PMC6620839</ArticleId>
            <ArticleId IdType="pubmed">31346333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hughes CS, Burden RE, Gilmore BF, Scott CJ. Strategies for detection and quantification of cysteine cathepsins-evolution from bench to bedside. Biochimie. 2016;122:48–61. doi: 10.1016/j.biochi.2015.07.029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biochi.2015.07.029</ArticleId>
            <ArticleId IdType="pubmed">26253694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verdoes M, Edgington LE, Scheeren FA, Leyva M, Blum G, Weiskopf K, Bachmann MH, Ellman JA, Bogyo M. A nonpeptidic cathepsin S activity-based probe for noninvasive optical imaging of tumor-associated macrophages. Chem Biol. 2012;19:619–628. doi: 10.1016/j.chembiol.2012.03.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chembiol.2012.03.012</ArticleId>
            <ArticleId IdType="pmc">PMC3361968</ArticleId>
            <ArticleId IdType="pubmed">22633413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agelaki S, Dragolia M, Markonanolaki H, Alkahtani S, Stournaras C, Georgoulias V, Kallergi G. Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients. Oncotarget. 2017;8:5309–5322. doi: 10.18632/oncotarget.14144.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.14144</ArticleId>
            <ArticleId IdType="pmc">PMC5354910</ArticleId>
            <ArticleId IdType="pubmed">28029660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amir E, Clemons M, Freedman OC, Miller N, Coleman RE, Purdie C, Jordan L, Quinlan P, Thompson AM. Tissue confirmation of disease recurrence in patients with breast cancer: pooled analysis of two large prospective studies. J Clin Oncol. 2010;28:1007. doi: 10.1200/jco.2010.28.15_suppl.1007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/jco.2010.28.15_suppl.1007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bernemann C, Huelsewig C, Kiesel L, Liedtke C. Targeting triple-negative breast cancer by conversion into HER2-positive cancer: a novel therapeutic approach. J Clin Oncol. 2012;30:e11534. doi: 10.1200/jco.2012.30.15_suppl.e11534.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/jco.2012.30.15_suppl.e11534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacot W, Cottu P, Berger F, Dubot C, Venat-Bouvet L, Lortholary A, Bourgeois H, Bollet M, Servent V, Luporsi E, et al.  Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial. Breast Cancer Res. 2019;21:121. doi: 10.1186/s13058-019-1215-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13058-019-1215-z</ArticleId>
            <ArticleId IdType="pmc">PMC6854749</ArticleId>
            <ArticleId IdType="pubmed">31727113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Subramaniyan V, Fuloria S, Gupta G, Kumar DH, Sekar M, Sathasivam KV, Sudhakar K, Alharbi KS, Al-Malki WH, Afzal O, et al.  A review on epidermal growth factor receptor's role in breast and non-small cell lung cancer. Chem Biol Interact. 2021;351:109735. doi: 10.1016/j.cbi.2021.109735.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cbi.2021.109735</ArticleId>
            <ArticleId IdType="pubmed">34742684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V, Klein C, Saini M, Bauerle T, Wallwiener M, et al.  Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol. 2013;31:539–544. doi: 10.1038/nbt.2576.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nbt.2576</ArticleId>
            <ArticleId IdType="pubmed">23609047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983–3988. doi: 10.1073/pnas.0530291100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0530291100</ArticleId>
            <ArticleId IdType="pmc">PMC153034</ArticleId>
            <ArticleId IdType="pubmed">12629218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berghoff AS, Liao Y, Karreman MA, Ilhan-Mutlu A, Gunkel K, Sprick MR, Eisen C, Kessler T, Osswald M, Wunsche S, et al.  Identification and characterization of Cancer cells that initiate metastases to the brain and other organs. Mol Cancer Res. 2021;19:688–701. doi: 10.1158/1541-7786.MCR-20-0863.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1541-7786.MCR-20-0863</ArticleId>
            <ArticleId IdType="pubmed">33443114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ren D, Zhu X, Kong R, Zhao Z, Sheng J, Wang J, Xu X, Liu J, Cui K, Zhang XH, et al.  Targeting brain-adaptive Cancer stem cells prohibits brain metastatic colonization of triple-negative breast Cancer. Cancer Res. 2018;78:2052–2064. doi: 10.1158/0008-5472.CAN-17-2994.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-17-2994</ArticleId>
            <ArticleId IdType="pmc">PMC5899649</ArticleId>
            <ArticleId IdType="pubmed">29567857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sullivan JP, Nahed BV, Madden MW, Oliveira SM, Springer S, Bhere D, Chi AS, Wakimoto H, Rothenberg SM, Sequist LV, et al.  Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discov. 2014;4:1299–1309. doi: 10.1158/2159-8290.CD-14-0471.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-14-0471</ArticleId>
            <ArticleId IdType="pmc">PMC4221467</ArticleId>
            <ArticleId IdType="pubmed">25139148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brlek P, Bukovac A, Kafka A, Pecina-Slaus N. TWIST1 upregulation affects E-cadherin expression in brain metastases. Clin Transl Oncol. 2021;23:1085–1095. doi: 10.1007/s12094-020-02496-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12094-020-02496-3</ArticleId>
            <ArticleId IdType="pubmed">33006113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vishnoi M, Peddibhotla S, Yin W. A TS, George GC, Hong DS, Marchetti D: the isolation and characterization of CTC subsets related to breast cancer dormancy. Sci Rep. 2015;5:17533. doi: 10.1038/srep17533.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep17533</ArticleId>
            <ArticleId IdType="pmc">PMC4668355</ArticleId>
            <ArticleId IdType="pubmed">26631983</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Nonneville A, Finetti P, Mamessier E, Bertucci F. RE: NDRG1 in aggressive breast Cancer progression and brain metastasis. J Natl Cancer Inst. 2022.</Citation>
        </Reference>
        <Reference>
          <Citation>Said HM, Safari R, Al-Kafaji G, Ernestus RI, Lohr M, Katzer A, Flentje M, Hagemann C. Time- and oxygen-dependent expression and regulation of NDRG1 in human brain cancer cells. Oncol Rep. 2017;37:3625–3634. doi: 10.3892/or.2017.5620.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/or.2017.5620</ArticleId>
            <ArticleId IdType="pubmed">28498432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schlee Villodre E, Hu X, Eckhardt BL, Larson R, Huo L, Yoon EC, et al. NDRG1 in aggressive breast Cancer progression and brain metastasis. J Natl Cancer Inst. 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Hanssen A, Riebensahm C, Mohme M, Joosse SA, Velthaus JL, Berger LA, et al. Frequency of circulating tumor cells (CTC) in Patients with brain metastases: implications as a risk assessment marker in oligo-metastatic disease, vol. 10. Cancers (Basel); 2018.</Citation>
        </Reference>
        <Reference>
          <Citation>Shirasawa M, Fukui T, Kusuhara S, Harada S, Nishinarita N, Hiyoshi Y, Ishihara M, Kasajima M, Igawa S, Yokoba M, et al.  Prognostic differences between oligometastatic and polymetastatic extensive disease-small cell lung cancer. PLoS One. 2019;14:e0214599. doi: 10.1371/journal.pone.0214599.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0214599</ArticleId>
            <ArticleId IdType="pmc">PMC6474590</ArticleId>
            <ArticleId IdType="pubmed">31002722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stephens SJ, Moravan MJ, Salama JK. Managing patients with Oligometastatic non-small-cell lung Cancer. J Oncol Pract. 2018;14:23–31. doi: 10.1200/JOP.2017.026500.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JOP.2017.026500</ArticleId>
            <ArticleId IdType="pubmed">29324212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17:559–572. doi: 10.1038/nri.2017.49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri.2017.49</ArticleId>
            <ArticleId IdType="pmc">PMC5731833</ArticleId>
            <ArticleId IdType="pubmed">28555670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rubio-Perez C, Planas-Rigol E, Trincado JL, Bonfill-Teixidor E, Arias A, Marchese D, Moutinho C, Serna G, Pedrosa L, Iurlaro R, et al.  Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment. Nat Commun. 2021;12:1503. doi: 10.1038/s41467-021-21789-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-021-21789-x</ArticleId>
            <ArticleId IdType="pmc">PMC7940606</ArticleId>
            <ArticleId IdType="pubmed">33686071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swarup V, Rajeswari MR. Circulating (cell-free) nucleic acids--a promising, non-invasive tool for early detection of several human diseases. FEBS Lett. 2007;581:795–799. doi: 10.1016/j.febslet.2007.01.051.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.febslet.2007.01.051</ArticleId>
            <ArticleId IdType="pubmed">17289032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang JY, Hsieh JS, Chang MY, Huang TJ, Chen FM, Cheng TL, Alexandersen K, Huang YS, Tzou WS, Lin SR. Molecular detection of APC, K- ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers. World J Surg. 2004;28:721–726.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15185002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shaw JA, Smith BM, Walsh T, Johnson S, Primrose L, Slade MJ, Walker RA, Coombes RC. Microsatellite alterations plasma DNA of primary breast cancer patients. Clin Cancer Res. 2000;6:1119–1124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10741742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, Beljanski M. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology. 1989;46:318–322. doi: 10.1159/000226740.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000226740</ArticleId>
            <ArticleId IdType="pubmed">2779946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37:646–650.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">837366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mandel P, Metais P. Nuclear acids in human blood plasma. C R Seances Soc Biol Fil. 1948;142:241–243.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18875018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, Knippers R. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001;61:1659–1665.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11245480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calabuig-Farinas S, Jantus-Lewintre E, Herreros-Pomares A, Camps C. Circulating tumor cells versus circulating tumor DNA in lung cancer-which one will win? Transl Lung Cancer Res. 2016;5:466–482. doi: 10.21037/tlcr.2016.10.02.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.21037/tlcr.2016.10.02</ArticleId>
            <ArticleId IdType="pmc">PMC5099512</ArticleId>
            <ArticleId IdType="pubmed">27826528</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lehmann-Werman R, Neiman D, Zemmour H, Moss J, Magenheim J, Vaknin-Dembinsky A, Rubertsson S, Nellgard B, Blennow K, Zetterberg H, et al.  Identification of tissue-specific cell death using methylation patterns of circulating DNA. Proc Natl Acad Sci U S A. 2016;113:E1826–E1834. doi: 10.1073/pnas.1519286113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1519286113</ArticleId>
            <ArticleId IdType="pmc">PMC4822610</ArticleId>
            <ArticleId IdType="pubmed">26976580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun K, Jiang P, Chan KC, Wong J, Cheng YK, Liang RH, Chan WK, Ma ES, Chan SL, Cheng SH, et al.  Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proc Natl Acad Sci U S A. 2015;112:E5503–E5512. doi: 10.1073/pnas.1422986112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1422986112</ArticleId>
            <ArticleId IdType="pmc">PMC4603482</ArticleId>
            <ArticleId IdType="pubmed">26392541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu J, Zhao H, Huang Y, Xu S, Zhou Y, Zhang W, Li J, Ming Y, Wang X, Zhao S, et al.  Genome-wide cell-free DNA methylation analyses improve accuracy of non-invasive diagnostic imaging for early-stage breast cancer. Mol Cancer. 2021;20:36. doi: 10.1186/s12943-021-01330-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12943-021-01330-w</ArticleId>
            <ArticleId IdType="pmc">PMC7893735</ArticleId>
            <ArticleId IdType="pubmed">33608029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deyell M, Garris CS, Laughney AM. Cancer metastasis as a non-healing wound. Br J Cancer. 2021;124:1491–1502. doi: 10.1038/s41416-021-01309-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41416-021-01309-w</ArticleId>
            <ArticleId IdType="pmc">PMC8076293</ArticleId>
            <ArticleId IdType="pubmed">33731858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lubotzky A, Zemmour H, Neiman D, Gotkine M, Loyfer N, Piyanzin S, et al. Liquid biopsy reveals collateral tissue damage in cancer. JCI Insight. 2022;7.</Citation>
        </Reference>
        <Reference>
          <Citation>Lam VK, Zhang J, Wu CC, Tran HT, Li L, Diao L, Wang J, Rinsurongkawong W, Raymond VM, Lanman RB, et al.  Genotype-specific differences in circulating tumor DNA levels in advanced NSCLC. J Thorac Oncol. 2021;16:601–609. doi: 10.1016/j.jtho.2020.12.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jtho.2020.12.011</ArticleId>
            <ArticleId IdType="pmc">PMC8012216</ArticleId>
            <ArticleId IdType="pubmed">33388476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chakrabarti S, Xie H, Urrutia R, Mahipal A. The promise of circulating tumor DNA (ctDNA). In: In the Management of Early-Stage Colon Cancer: a critical review, vol. 12. Cancers (Basel); 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, Amatu A, Lauricella C, et al.  Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med. 2015;21:795–801. doi: 10.1038/nm.3870.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.3870</ArticleId>
            <ArticleId IdType="pmc">PMC4868598</ArticleId>
            <ArticleId IdType="pubmed">26030179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diaz LA, Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, et al.  The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486:537–540. doi: 10.1038/nature11219.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature11219</ArticleId>
            <ArticleId IdType="pmc">PMC3436069</ArticleId>
            <ArticleId IdType="pubmed">22722843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tie J, Cohen JD, Wang Y, Christie M, Simons K, Lee M, Wong R, Kosmider S, Ananda S, McKendrick J, et al.  Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III Colon Cancer. JAMA Oncol. 2019;5:1710–1717. doi: 10.1001/jamaoncol.2019.3616.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2019.3616</ArticleId>
            <ArticleId IdType="pmc">PMC6802034</ArticleId>
            <ArticleId IdType="pubmed">31621801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu Z, Ding J, Ma Z, Sun R, Seoane JA, Scott Shaffer J, Suarez CJ, Berghoff AS, Cremolini C, Falcone A, et al.  Quantitative evidence for early metastatic seeding in colorectal cancer. Nat Genet. 2019;51:1113–1122. doi: 10.1038/s41588-019-0423-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41588-019-0423-x</ArticleId>
            <ArticleId IdType="pmc">PMC6982526</ArticleId>
            <ArticleId IdType="pubmed">31209394</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheung KJ, Padmanaban V, Silvestri V, Schipper K, Cohen JD, Fairchild AN, Gorin MA, Verdone JE, Pienta KJ, Bader JS, Ewald AJ. Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters. Proc Natl Acad Sci U S A. 2016;113:E854–E863.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4763783</ArticleId>
            <ArticleId IdType="pubmed">26831077</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shao J, Li J, Song L, He Q, Wu Y, Li L, Liu D, Wang C, Li W: The number of brain metastases predicts the survival of non-small cell lung cancer patients with EGFR mutation status. Cancer Rep (Hoboken) 2021:e1550.</Citation>
        </Reference>
        <Reference>
          <Citation>Shin DY, Na II, Kim CH, Park S, Baek H, Yang SH. EGFR mutation and brain metastasis in pulmonary adenocarcinomas. J Thorac Oncol. 2014;9:195–199. doi: 10.1097/JTO.0000000000000069.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/JTO.0000000000000069</ArticleId>
            <ArticleId IdType="pubmed">24419416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H, Wang Z, Zhang G, Zhang M, Zhang X, Li H, Zheng X, Ma Z. Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations. Cancer Med. 2020;9:487–495. doi: 10.1002/cam4.2706.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cam4.2706</ArticleId>
            <ArticleId IdType="pmc">PMC6970058</ArticleId>
            <ArticleId IdType="pubmed">31769228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johung KL, Yeh N, Desai NB, Williams TM, Lautenschlaeger T, Arvold ND, Ning MS, Attia A, Lovly CM, Goldberg S, et al.  Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung Cancer and brain metastasis. J Clin Oncol. 2016;34:123–129. doi: 10.1200/JCO.2015.62.0138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2015.62.0138</ArticleId>
            <ArticleId IdType="pmc">PMC5070549</ArticleId>
            <ArticleId IdType="pubmed">26438117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cacho-Diaz B, Garcia-Botello DR, Wegman-Ostrosky T, Reyes-Soto G, Ortiz-Sanchez E, Herrera-Montalvo LA. Tumor microenvironment differences between primary tumor and brain metastases. J Transl Med. 2020;18:1. doi: 10.1186/s12967-019-02189-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12967-019-02189-8</ArticleId>
            <ArticleId IdType="pmc">PMC6941297</ArticleId>
            <ArticleId IdType="pubmed">31900168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jin X, Demere Z, Nair K, Ali A, Ferraro GB, Natoli T, Deik A, Petronio L, Tang AA, Zhu C, et al.  A metastasis map of human cancer cell lines. Nature. 2020;588:331–336. doi: 10.1038/s41586-020-2969-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-020-2969-2</ArticleId>
            <ArticleId IdType="pmc">PMC8439149</ArticleId>
            <ArticleId IdType="pubmed">33299191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L, Zhang S, Yao J, Lowery FJ, Zhang Q, Huang WC, Li P, Li M, Wang X, Zhang C, et al.  Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature. 2015;527:100–104. doi: 10.1038/nature15376.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature15376</ArticleId>
            <ArticleId IdType="pmc">PMC4819404</ArticleId>
            <ArticleId IdType="pubmed">26479035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Richichi C, Fornasari L, Melloni GEM, Brescia P, Patane M, Del Bene M, Mustafa DAM, Kros JM, Pollo B, Pruneri G, et al.  Mutations targeting the coagulation pathway are enriched in brain metastases. Sci Rep. 2017;7:6573. doi: 10.1038/s41598-017-06811-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-017-06811-x</ArticleId>
            <ArticleId IdType="pmc">PMC5529435</ArticleId>
            <ArticleId IdType="pubmed">28747664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lo YMD, Han DSC, Jiang P, Chiu RWK. Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies. Science. 2021;372.</Citation>
        </Reference>
        <Reference>
          <Citation>Barciszewska AM. Global DNA demethylation as an epigenetic marker of human brain metastases. Biosci Rep. 2018;38.</Citation>
        </Reference>
        <Reference>
          <Citation>Fang P, Boehling NS, Koay EJ, Bucheit AD, Jakob JA, Settle SH, Brown PD, Davies MA, Sulman EP. Melanoma brain metastases harboring BRAF (V600K) or NRAS mutations are associated with an increased local failure rate following conventional therapy. J Neuro-Oncol. 2018;137:67–75. doi: 10.1007/s11060-017-2695-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-017-2695-2</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Menzies AM, Haydu LE, Visintin L, Carlino MS, Howle JR, Thompson JF, Kefford RF, Scolyer RA, Long GV. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res. 2012;18:3242–3249. doi: 10.1158/1078-0432.CCR-12-0052.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-12-0052</ArticleId>
            <ArticleId IdType="pubmed">22535154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bucheit AD, Syklawer E, Jakob JA, Bassett RL, Jr, Curry JL, Gershenwald JE, Kim KB, Hwu P, Lazar AJ, Davies MA. Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. Cancer. 2013;119:3821–3829. doi: 10.1002/cncr.28306.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.28306</ArticleId>
            <ArticleId IdType="pubmed">23922205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, Hamid O, Infante JR, Millward M, Pavlick AC, et al.  Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 2012;379:1893–1901. doi: 10.1016/S0140-6736(12)60398-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(12)60398-5</ArticleId>
            <ArticleId IdType="pmc">PMC4109288</ArticleId>
            <ArticleId IdType="pubmed">22608338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A, et al.  Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13:1087–1095. doi: 10.1016/S1470-2045(12)70431-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(12)70431-X</ArticleId>
            <ArticleId IdType="pubmed">23051966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Colombino M, Capone M, Lissia A, Cossu A, Rubino C, De Giorgi V, Massi D, Fonsatti E, Staibano S, Nappi O, et al.  BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol. 2012;30:2522–2529. doi: 10.1200/JCO.2011.41.2452.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2011.41.2452</ArticleId>
            <ArticleId IdType="pubmed">22614978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seremet T, Jansen Y, Planken S, Njimi H, Delaunoy M, El Housni H, Awada G, Schwarze JK, Keyaerts M, Everaert H, et al.  Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy. J Transl Med. 2019;17:303. doi: 10.1186/s12967-019-2051-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12967-019-2051-8</ArticleId>
            <ArticleId IdType="pmc">PMC6727487</ArticleId>
            <ArticleId IdType="pubmed">31488153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dzung A, Saltari A, Tiso N, Lyck R, Dummer R, Levesque MP. STK11 prevents invasion through STAT3/5 and FAK repression in cutaneous melanoma. J Invest Dermatol. 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–867. doi: 10.1038/nature01322.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature01322</ArticleId>
            <ArticleId IdType="pmc">PMC2803035</ArticleId>
            <ArticleId IdType="pubmed">12490959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maurya SK, Khan P, Rehman AU, Kanchan RK, Perumal N, Mahapatra S, et al. Rethinking the chemokine cascade in brain metastasis: preventive and therapeutic implications. Semin Cancer Biol. 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Khan GJ, Sun L, Abbas M, Naveed M, Jamshaid T, Baig M, Yuan S. In-vitro pre-treatment of Cancer cells with TGF-beta1: a novel approach of tail vein lung Cancer metastasis mouse model for anti-metastatic studies. Curr Mol Pharmacol. 2019;12:249–260. doi: 10.2174/1874467212666190306165703.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1874467212666190306165703</ArticleId>
            <ArticleId IdType="pubmed">30848226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilkinson RD, Williams R, Scott CJ, Burden RE. Cathepsin S: therapeutic, diagnostic, and prognostic potential. Biol Chem. 2015;396:867–882. doi: 10.1515/hsz-2015-0114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1515/hsz-2015-0114</ArticleId>
            <ArticleId IdType="pubmed">25872877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guerreiro EM, Ovstebo R, Thiede B, Costea DE, Soland TM, Kanli Galtung H. Cancer cell line-specific protein profiles in extracellular vesicles identified by proteomics. PLoS One. 2020;15:e0238591. doi: 10.1371/journal.pone.0238591.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0238591</ArticleId>
            <ArticleId IdType="pmc">PMC7473518</ArticleId>
            <ArticleId IdType="pubmed">32886718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y, Liu YS, Wu PF, Li Q, Dai WM, Yuan S, Xu ZH, Liu TT, Miao ZW, Fang WG, et al.  Brain microvascular endothelium induced-annexin A1 secretion contributes to small cell lung cancer brain metastasis. Int J Biochem Cell Biol. 2015;66:11–19. doi: 10.1016/j.biocel.2015.06.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biocel.2015.06.019</ArticleId>
            <ArticleId IdType="pubmed">26135980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen L, Hu X, Wu H, Jia Y, Liu J, Mu X, Wu H, Zhao Y. Over-expression of S100B protein as a serum marker of brain metastasis in non-small cell lung cancer and its prognostic value. Pathol Res Pract. 2019;215:427–432. doi: 10.1016/j.prp.2018.11.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.prp.2018.11.011</ArticleId>
            <ArticleId IdType="pubmed">30455129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mu S, Ma H, Shi J, Zhen D. The expression of S100B protein in serum of patients with brain metastases from small-cell lung cancer and its clinical significance. Oncol Lett. 2017;14:7107–7110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5754836</ArticleId>
            <ArticleId IdType="pubmed">29344141</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi H, Puvenna V, Brennan C, Mahmoud S, Wang XF, Phillips M, Janigro D, Mazzone P. S100B and S100B autoantibody as biomarkers for early detection of brain metastases in lung cancer. Transl Lung Cancer Res. 2016;5:413–419. doi: 10.21037/tlcr.2016.07.08.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.21037/tlcr.2016.07.08</ArticleId>
            <ArticleId IdType="pmc">PMC5009084</ArticleId>
            <ArticleId IdType="pubmed">27652205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bechmann T, Madsen JS, Brandslund I, Lund ED, Ormstrup T, Jakobsen EH, Jylling AM, Steffensen KD, Jakobsen A. Predicting brain metastases of breast cancer based on serum S100B and serum HER2. Oncol Lett. 2013;6:1265–1270. doi: 10.3892/ol.2013.1536.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol.2013.1536</ArticleId>
            <ArticleId IdType="pmc">PMC3813762</ArticleId>
            <ArticleId IdType="pubmed">24179506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang H, Liu J, Meng Q, Niu G. Multidrug resistance protein and topoisomerase 2 alpha expression in non-small cell lung cancer are related with brain metastasis postoperatively. Int J Clin Exp Pathol. 2015;8:11537–11542.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4637703</ArticleId>
            <ArticleId IdType="pubmed">26617887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maliyakkal N, Appadath Beeran A, Udupa N. Nanoparticles of cisplatin augment drug accumulations and inhibit multidrug resistance transporters in human glioblastoma cells. Saudi Pharm J. 2021;29:857–873. doi: 10.1016/j.jsps.2021.07.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jsps.2021.07.001</ArticleId>
            <ArticleId IdType="pmc">PMC8363105</ArticleId>
            <ArticleId IdType="pubmed">34408546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mansouri A, Padmanaban V, Aregawi D, Glantz M. VEGF and immune checkpoint inhibition for prevention of brain metastases: systematic review and Meta-analysis. Neurology. 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Villodre ES, Hu X, Larson R, Finetti P, Gomez K, Balema W, Stecklein SR, Santiago-Sanchez G, Krishnamurthy S, Song J, et al.  Lipocalin 2 promotes inflammatory breast cancer tumorigenesis and skin invasion. Mol Oncol. 2021;15:2752–2765. doi: 10.1002/1878-0261.13074.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1878-0261.13074</ArticleId>
            <ArticleId IdType="pmc">PMC8486564</ArticleId>
            <ArticleId IdType="pubmed">34342930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Priego N, Zhu L, Monteiro C, Mulders M, Wasilewski D, Bindeman W, Doglio L, Martinez L, Martinez-Saez E, Ramon YCS, et al.  Author correction: STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis. Nat Med. 2018;24:1481. doi: 10.1038/s41591-018-0108-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-018-0108-5</ArticleId>
            <ArticleId IdType="pubmed">29921958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ashraf MI, Schwelberger HG, Brendel KA, Feurle J, Andrassy J, Kotsch K, Regele H, Pratschke J, Maier HT, Aigner F. Exogenous Lipocalin 2 ameliorates acute rejection in a mouse model of renal transplantation. Am J Transplant. 2016;16:808–820. doi: 10.1111/ajt.13521.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ajt.13521</ArticleId>
            <ArticleId IdType="pmc">PMC4996417</ArticleId>
            <ArticleId IdType="pubmed">26595644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaur S, Chang T, Singh SP, Lim L, Mannan P, Garfield SH, Pendrak ML, Soto-Pantoja DR, Rosenberg AZ, Jin S, Roberts DD. CD47 signaling regulates the immunosuppressive activity of VEGF in T cells. J Immunol. 2014;193:3914–3924. doi: 10.4049/jimmunol.1303116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1303116</ArticleId>
            <ArticleId IdType="pmc">PMC4185246</ArticleId>
            <ArticleId IdType="pubmed">25200950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thorne M, Moore CS, Robertson GS. Lack of TIMP-1 increases severity of experimental autoimmune encephalomyelitis: effects of darbepoetin alfa on TIMP-1 null and wild-type mice. J Neuroimmunol. 2009;211:92–100. doi: 10.1016/j.jneuroim.2009.04.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2009.04.003</ArticleId>
            <ArticleId IdType="pubmed">19428125</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reynes G, Vila V, Martin M, Parada A, Fleitas T, Reganon E, Martinez-Sales V. Circulating markers of angiogenesis, inflammation, and coagulation in patients with glioblastoma. J Neuro-Oncol. 2011;102:35–41. doi: 10.1007/s11060-010-0290-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-010-0290-x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim LS, Huang S, Lu W, Lev DC, Price JE. Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice. Clin Exp Metastasis. 2004;21:107–118. doi: 10.1023/B:CLIN.0000024761.00373.55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1023/B:CLIN.0000024761.00373.55</ArticleId>
            <ArticleId IdType="pubmed">15168728</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dao T, Gapihan G, Leboeuf C, Hamdan D, Feugeas JP, Boudabous H, Zelek L, Miquel C, Tran T, Monnot C, et al.  Expression of angiopoietin-like 4 fibrinogen-like domain (cANGPTL4) increases risk of brain metastases in women with breast cancer. Oncotarget. 2020;11:1590–1602. doi: 10.18632/oncotarget.27553.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.27553</ArticleId>
            <ArticleId IdType="pmc">PMC7210011</ArticleId>
            <ArticleId IdType="pubmed">32405335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dai J, Cimino PJ, Gouin KH, 3rd, Grzelak CA, Barrett A, Lim AR, Long A, Weaver S, Saldin LT, Uzamere A, et al.  Astrocytic laminin-211 drives disseminated breast tumor cell dormancy in brain. Nat Can. 2022;3:25–42. doi: 10.1038/s43018-021-00297-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s43018-021-00297-3</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kittur SD, Adler WH, Martin GR, Schapiro MB, Rapoport SI, Gunzler V. Laminin concentrations in serum and cerebrospinal fluid in aging and Alzheimer's disease. Int J Dev Neurosci. 1993;11:95–99. doi: 10.1016/0736-5748(93)90038-F.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0736-5748(93)90038-F</ArticleId>
            <ArticleId IdType="pubmed">8488758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alzial G, Renoult O, Paris F, Gratas C, Clavreul A, Pecqueur C. Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma. Oncogene. 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Martinez-Reyes I, Chandel NS. Cancer metabolism: looking forward. Nat Rev Cancer. 2021;21:669–680. doi: 10.1038/s41568-021-00378-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41568-021-00378-6</ArticleId>
            <ArticleId IdType="pubmed">34272515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yen KE, Bittinger MA, Su SM, Fantin VR. Cancer-associated IDH mutations: biomarker and therapeutic opportunities. Oncogene. 2010;29:6409–6417. doi: 10.1038/onc.2010.444.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2010.444</ArticleId>
            <ArticleId IdType="pubmed">20972461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462:739–744. doi: 10.1038/nature08617.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature08617</ArticleId>
            <ArticleId IdType="pmc">PMC2818760</ArticleId>
            <ArticleId IdType="pubmed">19935646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davis RT, Blake K, Ma D, Gabra MBI, Hernandez GA, Phung AT, Yang Y, Maurer D, Lefebvre A, Alshetaiwi H, et al.  Transcriptional diversity and bioenergetic shift in human breast cancer metastasis revealed by single-cell RNA sequencing. Nat Cell Biol. 2020;22:310–320. doi: 10.1038/s41556-020-0477-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41556-020-0477-0</ArticleId>
            <ArticleId IdType="pubmed">32144411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruiz-Rodado V, Brender JR, Cherukuri MK, Gilbert MR, Larion M. Magnetic resonance spectroscopy for the study of cns malignancies. Prog Nucl Magn Reson Spectrosc. 2021;122:23–41. doi: 10.1016/j.pnmrs.2020.11.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pnmrs.2020.11.001</ArticleId>
            <ArticleId IdType="pmc">PMC7910526</ArticleId>
            <ArticleId IdType="pubmed">33632416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith JK, Castillo M, Kwock L. MR spectroscopy of brain tumors. Magn Reson Imaging Clin N Am. 2003;11(415-429):v–vi.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang FX, Chen K, Huang FQ, Alolga RN, Ma J, Wu ZX, Fan Y, Ma G, Guan M. Cerebrospinal fluid-based metabolomics to characterize different types of brain tumors. J Neurol. 2020;267:984–993. doi: 10.1007/s00415-019-09665-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-019-09665-7</ArticleId>
            <ArticleId IdType="pubmed">31822990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ge Z, Feng P, Zhang Z, Li J, Yu Q. Identification of novel serum metabolic biomarkers as indicators in the progression of intravenous Leiomyomatosis: a high performance liquid chromatography-tandem mass spectrometry-based study. Front Cell Dev Biol. 2021;9:695540. doi: 10.3389/fcell.2021.695540.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fcell.2021.695540</ArticleId>
            <ArticleId IdType="pmc">PMC8297591</ArticleId>
            <ArticleId IdType="pubmed">34307370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferraro GB, Ali A, Luengo A, Kodack DP, Deik A, Abbott KL, Bezwada D, Blanc L, Prideaux B, Jin X, et al.  Fatty acid synthesis is required for breast Cancer brain metastasis. Nat Can. 2021;2:414–428. doi: 10.1038/s43018-021-00183-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s43018-021-00183-y</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saito K, Hattori K, Andou T, Satomi Y, Gotou M, Kobayashi H, et al. Characterization of postprandial effects on CSF metabolomics: a pilot study with parallel comparison to plasma. Metabolites. 2020;10.</Citation>
        </Reference>
        <Reference>
          <Citation>Chen EI, Hewel J, Krueger JS, Tiraby C, Weber MR, Kralli A, Becker K, Yates JR, 3rd, Felding-Habermann B. Adaptation of energy metabolism in breast cancer brain metastases. Cancer Res. 2007;67:1472–1486. doi: 10.1158/0008-5472.CAN-06-3137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-06-3137</ArticleId>
            <ArticleId IdType="pubmed">17308085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Özer Ö, Nemutlu E, Eylem CC, Kır S, Reçber T, Aktas BY, Kars A, Aksoy S. Detection of brain metastasis by metabolomics methods in metastatic breast cancer patients. J Clin Oncol. 2019;37:e12572. doi: 10.1200/JCO.2019.37.15_suppl.e12572.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2019.37.15_suppl.e12572</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Larkin JR, Dickens AM, Claridge TD, Bristow C, Andreou K, Anthony DC, Sibson NR. Early diagnosis of brain metastases using a biofluids-metabolomics approach in mice. Theranostics. 2016;6:2161–2169. doi: 10.7150/thno.16538.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/thno.16538</ArticleId>
            <ArticleId IdType="pmc">PMC5135440</ArticleId>
            <ArticleId IdType="pubmed">27924154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anami S, Doi H, Nakamatsu K, Uehara T, Wada Y, Fukuda K, et al. Serum lactate dehydrogenase predicts survival in small-cell lung cancer patients with brain metastases that were treated with whole-brain radiotherapy. J Radiat Res. 2019;60(257-263).</Citation>
        </Reference>
        <Reference>
          <Citation>Dong T, Liu Z, Xuan Q, Wang Z, Ma W, Zhang Q. Tumor LDH-A expression and serum LDH status are two metabolic predictors for triple negative breast cancer brain metastasis. Sci Rep. 2017;7:6069. doi: 10.1038/s41598-017-06378-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-017-06378-7</ArticleId>
            <ArticleId IdType="pmc">PMC5519725</ArticleId>
            <ArticleId IdType="pubmed">28729678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dai J, Su Y, Zhong S, Cong L, Liu B, Yang J, Tao Y, He Z, Chen C, Jiang Y. Exosomes: key players in cancer and potential therapeutic strategy. Signal Transduct Target Ther. 2020;5:145. doi: 10.1038/s41392-020-00261-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41392-020-00261-0</ArticleId>
            <ArticleId IdType="pmc">PMC7406508</ArticleId>
            <ArticleId IdType="pubmed">32759948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhang L, Yu D. Exosomes in cancer development, metastasis, and immunity. Biochim Biophys Acta Rev Cancer. 2019;1871:455–468. doi: 10.1016/j.bbcan.2019.04.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbcan.2019.04.004</ArticleId>
            <ArticleId IdType="pmc">PMC6542596</ArticleId>
            <ArticleId IdType="pubmed">31047959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thery C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, Antoniou A, Arab T, Archer F, Atkin-Smith GK, et al.  Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7:1535750. doi: 10.1080/20013078.2018.1535750.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/20013078.2018.1535750</ArticleId>
            <ArticleId IdType="pmc">PMC6322352</ArticleId>
            <ArticleId IdType="pubmed">30637094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thery C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002;2:569–579. doi: 10.1038/nri855.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri855</ArticleId>
            <ArticleId IdType="pubmed">12154376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoshino A, Kim HS, Bojmar L, Gyan KE, Cioffi M, Hernandez J, Zambirinis CP, Rodrigues G, Molina H, Heissel S, et al.  Extracellular vesicle and particle biomarkers define multiple human cancers. Cell. 2020;182(1044-1061):e1018.</Citation>
        </Reference>
        <Reference>
          <Citation>Yang Z, Shi J, Xie J, Wang Y, Sun J, Liu T, Zhao Y, Zhao X, Wang X, Ma Y, et al.  Author correction: large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation. Nat Biomed Eng. 2021;5:944–945. doi: 10.1038/s41551-021-00725-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41551-021-00725-w</ArticleId>
            <ArticleId IdType="pubmed">34131325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Banks WA, Sharma P, Bullock KM, Hansen KM, Ludwig N, Whiteside TL. Transport of extracellular vesicles across the blood-brain barrier: brain pharmacokinetics and effects of inflammation. Int J Mol Sci. 2020;21.</Citation>
        </Reference>
        <Reference>
          <Citation>Tomasetti M, Lee W, Santarelli L, Neuzil J. Exosome-derived microRNAs in cancer metabolism: possible implications in cancer diagnostics and therapy. Exp Mol Med. 2017;49:e285. doi: 10.1038/emm.2016.153.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/emm.2016.153</ArticleId>
            <ArticleId IdType="pmc">PMC5291842</ArticleId>
            <ArticleId IdType="pubmed">28104913</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang H, Deng T, Liu R, Bai M, Zhou L, Wang X, Li S, Wang X, Yang H, Li J, et al.  Exosome-delivered EGFR regulates liver microenvironment to promote gastric cancer liver metastasis. Nat Commun. 2017;8:15016. doi: 10.1038/ncomms15016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms15016</ArticleId>
            <ArticleId IdType="pmc">PMC5394240</ArticleId>
            <ArticleId IdType="pubmed">28393839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo Y, Ji X, Liu J, Fan D, Zhou Q, Chen C, Wang W, Wang G, Wang H, Yuan W, et al.  Effects of exosomes on pre-metastatic niche formation in tumors. Mol Cancer. 2019;18:39. doi: 10.1186/s12943-019-0995-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12943-019-0995-1</ArticleId>
            <ArticleId IdType="pmc">PMC6413442</ArticleId>
            <ArticleId IdType="pubmed">30857545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, Molina H, Kohsaka S, Di Giannatale A, Ceder S, et al.  Tumour exosome integrins determine organotropic metastasis. Nature. 2015;527:329–335. doi: 10.1038/nature15756.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature15756</ArticleId>
            <ArticleId IdType="pmc">PMC4788391</ArticleId>
            <ArticleId IdType="pubmed">26524530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou B, Xu K, Zheng X, Chen T, Wang J, Song Y, Shao Y, Zheng S. Application of exosomes as liquid biopsy in clinical diagnosis. Signal Transduct Target Ther. 2020;5:144. doi: 10.1038/s41392-020-00258-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41392-020-00258-9</ArticleId>
            <ArticleId IdType="pmc">PMC7400738</ArticleId>
            <ArticleId IdType="pubmed">32747657</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allelein S, Medina-Perez P, Lopes ALH, Rau S, Hause G, Kolsch A, Kuhlmeier D. Potential and challenges of specifically isolating extracellular vesicles from heterogeneous populations. Sci Rep. 2021;11:11585. doi: 10.1038/s41598-021-91129-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-021-91129-y</ArticleId>
            <ArticleId IdType="pmc">PMC8172572</ArticleId>
            <ArticleId IdType="pubmed">34079007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bojmar L, Kim HS, Tobias GC, Pelissier Vatter FA, Lucotti S, Gyan KE, Kenific CM, Wan Z, Kim KA, Kim D, et al.  Extracellular vesicle and particle isolation from human and murine cell lines, tissues, and bodily fluids. STAR Protoc. 2021;2:100225. doi: 10.1016/j.xpro.2020.100225.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.xpro.2020.100225</ArticleId>
            <ArticleId IdType="pmc">PMC7988237</ArticleId>
            <ArticleId IdType="pubmed">33786456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang H, Lyden D. Asymmetric-flow field-flow fractionation technology for exomere and small extracellular vesicle separation and characterization. Nat Protoc. 2019;14:1027–1053. doi: 10.1038/s41596-019-0126-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41596-019-0126-x</ArticleId>
            <ArticleId IdType="pmc">PMC6733524</ArticleId>
            <ArticleId IdType="pubmed">30833697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sidhom K, Obi PO, Saleem A. A review of Exosomal isolation methods: is size exclusion chromatography the best option? Int J Mol Sci. 2020;21.</Citation>
        </Reference>
        <Reference>
          <Citation>Zeng Z, Li Y, Pan Y, Lan X, Song F, Sun J, Zhou K, Liu X, Ren X, Wang F, et al.  Cancer-derived exosomal miR-25-3p promotes pre-metastatic niche formation by inducing vascular permeability and angiogenesis. Nat Commun. 2018;9:5395. doi: 10.1038/s41467-018-07810-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-018-07810-w</ArticleId>
            <ArticleId IdType="pmc">PMC6300604</ArticleId>
            <ArticleId IdType="pubmed">30568162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meltzer S, Bjornetro T, Lyckander LG, Flatmark K, Dueland S, Samiappan R, Johansen C, Kalanxhi E, Ree AH, Redalen KR. Circulating Exosomal miR-141-3p and miR-375 in metastatic progression of rectal Cancer. Transl Oncol. 2019;12:1038–1044. doi: 10.1016/j.tranon.2019.04.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tranon.2019.04.014</ArticleId>
            <ArticleId IdType="pmc">PMC6542769</ArticleId>
            <ArticleId IdType="pubmed">31146167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teng Y, Ren Y, Hu X, Mu J, Samykutty A, Zhuang X, Deng Z, Kumar A, Zhang L, Merchant ML, et al.  MVP-mediated exosomal sorting of miR-193a promotes colon cancer progression. Nat Commun. 2017;8:14448. doi: 10.1038/ncomms14448.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms14448</ArticleId>
            <ArticleId IdType="pmc">PMC5321731</ArticleId>
            <ArticleId IdType="pubmed">28211508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang P, Wu Y, Chen W, Zhang M, Qin J. Malignant melanoma-derived exosomes induce endothelial damage and glial activation on a human BBB Chip model. Biosensors (Basel). 2022;12.</Citation>
        </Reference>
        <Reference>
          <Citation>Han M, Hu J, Lu P, Cao H, Yu C, Li X, Qian X, Yang X, Yang Y, Han N, et al.  Exosome-transmitted miR-567 reverses trastuzumab resistance by inhibiting ATG5 in breast cancer. Cell Death Dis. 2020;11:43. doi: 10.1038/s41419-020-2250-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-020-2250-5</ArticleId>
            <ArticleId IdType="pmc">PMC6976584</ArticleId>
            <ArticleId IdType="pubmed">31969559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu T, Zhang X, Du L, Wang Y, Liu X, Tian H, Wang L, Li P, Zhao Y, Duan W, et al.  Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer. Mol Cancer. 2019;18:43. doi: 10.1186/s12943-019-0981-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12943-019-0981-7</ArticleId>
            <ArticleId IdType="pmc">PMC6423768</ArticleId>
            <ArticleId IdType="pubmed">30890168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Serrati S, Guida M, Di Fonte R, De Summa S, Strippoli S, Iacobazzi RM, Quarta A, De Risi I, Guida G, Paradiso A, et al.  Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma. Mol Cancer. 2022;21:20. doi: 10.1186/s12943-021-01490-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12943-021-01490-9</ArticleId>
            <ArticleId IdType="pmc">PMC8764806</ArticleId>
            <ArticleId IdType="pubmed">35042524</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seguin L, Desgrosellier JS, Weis SM, Cheresh DA. Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. Trends Cell Biol. 2015;25:234–240. doi: 10.1016/j.tcb.2014.12.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tcb.2014.12.006</ArticleId>
            <ArticleId IdType="pmc">PMC4380531</ArticleId>
            <ArticleId IdType="pubmed">25572304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vogetseder A, Thies S, Ingold B, Roth P, Weller M, Schraml P, Goodman SL, Moch H. Alphav-integrin isoform expression in primary human tumors and brain metastases. Int J Cancer. 2013;133:2362–2371. doi: 10.1002/ijc.28267.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.28267</ArticleId>
            <ArticleId IdType="pubmed">23661241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kinjyo I, Bragin D, Grattan R, Winter SS, Wilson BS. Leukemia-derived exosomes and cytokines pave the way for entry into the brain. J Leukoc Biol. 2019;105:741–753. doi: 10.1002/JLB.3A0218-054R.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/JLB.3A0218-054R</ArticleId>
            <ArticleId IdType="pmc">PMC7200047</ArticleId>
            <ArticleId IdType="pubmed">30702754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu ZH, Miao ZW, Jiang QZ, Gan DX, Wei XG, Xue XZ, Li JQ, Zheng F, Qin XX, Fang WG, et al.  Brain microvascular endothelial cell exosome-mediated S100A16 up-regulation confers small-cell lung cancer cell survival in brain. FASEB J. 2019;33:1742–1757. doi: 10.1096/fj.201800428R.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1096/fj.201800428R</ArticleId>
            <ArticleId IdType="pubmed">30183374</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Camacho L, Guerrero P, Marchetti D. MicroRNA and protein profiling of brain metastasis competent cell-derived exosomes. PLoS One. 2013;8:e73790. doi: 10.1371/journal.pone.0073790.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0073790</ArticleId>
            <ArticleId IdType="pmc">PMC3774795</ArticleId>
            <ArticleId IdType="pubmed">24066071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin TC, Yang CH, Cheng LH, Chang WT, Lin YR, Cheng HC. Fibronectin in Cancer: friend or foe. Cells. 2019;9.</Citation>
        </Reference>
        <Reference>
          <Citation>Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer. 2011;11:558–572. doi: 10.1038/nrc3090.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc3090</ArticleId>
            <ArticleId IdType="pubmed">21734724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alao JP. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer. 2007;6:24. doi: 10.1186/1476-4598-6-24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1476-4598-6-24</ArticleId>
            <ArticleId IdType="pmc">PMC1851974</ArticleId>
            <ArticleId IdType="pubmed">17407548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maji S, Chaudhary P, Akopova I, Nguyen PM, Hare RJ, Gryczynski I, Vishwanatha JK. Exosomal Annexin II promotes angiogenesis and breast Cancer metastasis. Mol Cancer Res. 2017;15:93–105. doi: 10.1158/1541-7786.MCR-16-0163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1541-7786.MCR-16-0163</ArticleId>
            <ArticleId IdType="pmc">PMC5215956</ArticleId>
            <ArticleId IdType="pubmed">27760843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khan P, Siddiqui JA, Lakshmanan I, Ganti AK, Salgia R, Jain M, Batra SK, Nasser MW. RNA-based therapies: a cog in the wheel of lung cancer defense. Mol Cancer. 2021;20:54. doi: 10.1186/s12943-021-01338-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12943-021-01338-2</ArticleId>
            <ArticleId IdType="pmc">PMC7977189</ArticleId>
            <ArticleId IdType="pubmed">33740988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giannopoulou L, Zavridou M, Kasimir-Bauer S, Lianidou ES. Liquid biopsy in ovarian cancer: the potential of circulating miRNAs and exosomes. Transl Res. 2019;205:77–91. doi: 10.1016/j.trsl.2018.10.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.trsl.2018.10.003</ArticleId>
            <ArticleId IdType="pubmed">30391474</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drusco A, Bottoni A, Lagana A, Acunzo M, Fassan M, Cascione L, Antenucci A, Kumchala P, Vicentini C, Gardiman MP, et al.  A differentially expressed set of microRNAs in cerebro-spinal fluid (CSF) can diagnose CNS malignancies. Oncotarget. 2015;6:20829–20839. doi: 10.18632/oncotarget.4096.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.4096</ArticleId>
            <ArticleId IdType="pmc">PMC4673232</ArticleId>
            <ArticleId IdType="pubmed">26246487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shipman L. Microenvironment: astrocytes silence PTEN to promote brain metastasis. Nat Rev Cancer. 2015;15:695. doi: 10.1038/nrc4045.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc4045</ArticleId>
            <ArticleId IdType="pubmed">26563461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aleckovic M, Kang Y. Welcoming treat: astrocyte-derived exosomes induce PTEN suppression to Foster brain metastasis. Cancer Cell. 2015;28:554–556. doi: 10.1016/j.ccell.2015.10.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2015.10.010</ArticleId>
            <ArticleId IdType="pubmed">26555172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xing F, Liu Y, Wu SY, Wu K, Sharma S, Mo YY, Feng J, Sanders S, Jin G, Singh R, et al.  Correction: loss of XIST in breast Cancer activates MSN-c-met and reprograms microglia via Exosomal miRNA to promote brain metastasis. Cancer Res. 2021;81:5582. doi: 10.1158/0008-5472.CAN-21-3056.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-21-3056</ArticleId>
            <ArticleId IdType="pubmed">34725134</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fong MY, Wang SE. The exploits of cancer's greedy sweet-tooth. Cell Cycle. 2015;14:1768–1769. doi: 10.1080/15384101.2015.1046786.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/15384101.2015.1046786</ArticleId>
            <ArticleId IdType="pmc">PMC4615071</ArticleId>
            <ArticleId IdType="pubmed">25928026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schimmel RJ. Role of cell calcium in alpha-1 adrenergic receptor control of arachidonic acid release from brown adipocytes. Cell Signal. 1989;1:607–616. doi: 10.1016/0898-6568(89)90069-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0898-6568(89)90069-7</ArticleId>
            <ArticleId IdType="pubmed">2561950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu X, Somlo G, Yu Y, Palomares MR, Li AX, Zhou W, Chow A, Yen Y, Rossi JJ, Gao H, et al.  De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer. J Transl Med. 2012;10:42. doi: 10.1186/1479-5876-10-42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1479-5876-10-42</ArticleId>
            <ArticleId IdType="pmc">PMC3342150</ArticleId>
            <ArticleId IdType="pubmed">22400902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sato J, Shimomura A, Kawauchi J, Matsuzaki J, Yamamoto Y, Takizawa S, Sakamoto H, Ohno M, Narita Y, Ochiya T, Tamura K. Brain metastasis-related microRNAs in patients with advanced breast cancer. PLoS One. 2019;14:e0221538. doi: 10.1371/journal.pone.0221538.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0221538</ArticleId>
            <ArticleId IdType="pmc">PMC6788729</ArticleId>
            <ArticleId IdType="pubmed">31603918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu D, Deng S, Li L, Liu T, Zhang T, Li J, Yu Y, Xu Y. Correction: TGF-beta1-mediated exosomal lnc-MMP2-2 increases blood-brain barrier permeability via the miRNA-1207-5p/EPB41L5 axis to promote non-small cell lung cancer brain metastasis. Cell Death Dis. 2021;12:916. doi: 10.1038/s41419-021-04072-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-021-04072-1</ArticleId>
            <ArticleId IdType="pmc">PMC8497500</ArticleId>
            <ArticleId IdType="pubmed">34620832</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu D, Deng S, Li L, Liu T, Zhang T, Li J, Yu Y, Xu Y. TGF-beta1-mediated exosomal lnc-MMP2-2 increases blood-brain barrier permeability via the miRNA-1207-5p/EPB41L5 axis to promote non-small cell lung cancer brain metastasis. Cell Death Dis. 2021;12:721. doi: 10.1038/s41419-021-04004-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-021-04004-z</ArticleId>
            <ArticleId IdType="pmc">PMC8292445</ArticleId>
            <ArticleId IdType="pubmed">34285192</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karimpour M, Ravanbakhsh R, Maydanchi M, Rajabi A, Azizi F, Saber A. Cancer driver gene and non-coding RNA alterations as biomarkers of brain metastasis in lung cancer: a review of the literature. Biomed Pharmacother. 2021;143:112190. doi: 10.1016/j.biopha.2021.112190.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biopha.2021.112190</ArticleId>
            <ArticleId IdType="pubmed">34560543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun G, Ding X, Bi N, Wang Z, Wu L, Zhou W, Zhao Z, Wang J, Zhang W, Fan J, et al.  Correction: molecular predictors of brain metastasis-related microRNAs in lung adenocarcinoma. PLoS Genet. 2020;16:e1009139. doi: 10.1371/journal.pgen.1009139.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pgen.1009139</ArticleId>
            <ArticleId IdType="pmc">PMC7556456</ArticleId>
            <ArticleId IdType="pubmed">33052902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun G, Ding X, Bi N, Wu L, Wang J, Zhang W, Dong X, Lv N, Song Y, Zhan Q, Wang L. MiR-423-5p in brain metastasis: potential role in diagnostics and molecular biology. Cell Death Dis. 2018;9:936. doi: 10.1038/s41419-018-0955-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-018-0955-5</ArticleId>
            <ArticleId IdType="pmc">PMC6141540</ArticleId>
            <ArticleId IdType="pubmed">30224667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao C, Xu Y, Zhang Y, Tan W, Xue J, Yang Z, Zhang Y, Lu Y, Hu X. Downregulation of miR-145 contributes to lung adenocarcinoma cell growth to form brain metastases. Oncol Rep. 2013;30:2027–2034. doi: 10.3892/or.2013.2728.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/or.2013.2728</ArticleId>
            <ArticleId IdType="pmc">PMC3820619</ArticleId>
            <ArticleId IdType="pubmed">24026105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arora S, Ranade AR, Tran NL, Nasser S, Sridhar S, Korn RL, Ross JT, Dhruv H, Foss KM, Sibenaller Z, et al.  MicroRNA-328 is associated with (non-small) cell lung cancer (NSCLC) brain metastasis and mediates NSCLC migration. Int J Cancer. 2011;129:2621–2631. doi: 10.1002/ijc.25939.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.25939</ArticleId>
            <ArticleId IdType="pmc">PMC3154499</ArticleId>
            <ArticleId IdType="pubmed">21448905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jia W, Lu R, Martin TA, Jiang WG. The role of claudin-5 in blood-brain barrier (BBB) and brain metastases (review) Mol Med Rep. 2014;9:779–785. doi: 10.3892/mmr.2013.1875.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/mmr.2013.1875</ArticleId>
            <ArticleId IdType="pubmed">24366267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma SC, Li Q, Peng JY, Zhouwen JL, Diao JF, Niu JX, Wang X, Guan XD, Jia W, Jiang WG. Claudin-5 regulates blood-brain barrier permeability by modifying brain microvascular endothelial cell proliferation, migration, and adhesion to prevent lung cancer metastasis. CNS Neurosci Ther. 2017;23:947–960. doi: 10.1111/cns.12764.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cns.12764</ArticleId>
            <ArticleId IdType="pmc">PMC6492739</ArticleId>
            <ArticleId IdType="pubmed">28961379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giannoudis A, Clarke K, Zakaria R, Vareslija D, Farahani M, Rainbow L, Platt-Higgins A, Ruthven S, Brougham KA, Rudland PS, et al.  A novel panel of differentially-expressed microRNAs in breast cancer brain metastasis may predict patient survival. Sci Rep. 2019;9:18518. doi: 10.1038/s41598-019-55084-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-019-55084-z</ArticleId>
            <ArticleId IdType="pmc">PMC6897960</ArticleId>
            <ArticleId IdType="pubmed">31811234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morad G, Daisy CC, Otu HH, Libermann TA, Dillon ST, Moses MA. Cdc42-dependent transfer of mir301 from breast Cancer-derived extracellular vesicles regulates the matrix modulating ability of astrocytes at the blood-brain barrier. Int J Mol Sci. 2020;21.</Citation>
        </Reference>
        <Reference>
          <Citation>Guglielmi L, Nardella M, Musa C, Cifola I, Porru M, Cardinali B, et al. Circulating miRNAs in small extracellular vesicles secreted by a human melanoma xenograft in mouse brains. Cancers (Basel). 2020;12.</Citation>
        </Reference>
        <Reference>
          <Citation>Fu B, Liu W, Zhu C, Li P, Wang L, Pan L, Li K, Cai P, Meng M, Wang Y, et al.  Circular RNA circBCBM1 promotes breast cancer brain metastasis by modulating miR-125a/BRD4 axis. Int J Biol Sci. 2021;17:3104–3117. doi: 10.7150/ijbs.58916.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/ijbs.58916</ArticleId>
            <ArticleId IdType="pmc">PMC8375234</ArticleId>
            <ArticleId IdType="pubmed">34421353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fu B, Zhang A, Li M, Pan L, Tang W, An M, Liu W, Zhang J. Circular RNA profile of breast cancer brain metastasis: identification of potential biomarkers and therapeutic targets. Epigenomics. 2018;10:1619–1630. doi: 10.2217/epi-2018-0090.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/epi-2018-0090</ArticleId>
            <ArticleId IdType="pubmed">30810051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang HD, Jiang LH, Hou JC, Zhong SL, Zhou SY, Zhu LP, Li J, Wang DD, Sun DW, Ji ZL, Tang JH. Circular RNA hsa_circ_0052112 promotes cell migration and invasion by acting as sponge for miR-125a-5p in breast cancer. Biomed Pharmacother. 2018;107:1342–1353. doi: 10.1016/j.biopha.2018.08.030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biopha.2018.08.030</ArticleId>
            <ArticleId IdType="pubmed">30257349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu Y, Chen L, Li L, Cao Y. Exosomes derived from brain metastatic breast Cancer cells destroy the blood-brain barrier by carrying lncRNA GS1-600G8.5. Biomed Res Int. 2020;2020(7461727).</Citation>
        </Reference>
        <Reference>
          <Citation>Wang S, Liang K, Hu Q, Li P, Song J, Yang Y, Yao J, Mangala LS, Li C, Yang W, et al.  JAK2-binding long noncoding RNA promotes breast cancer brain metastasis. J Clin Invest. 2017;127:4498–4515. doi: 10.1172/JCI91553.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI91553</ArticleId>
            <ArticleId IdType="pmc">PMC5707156</ArticleId>
            <ArticleId IdType="pubmed">29130936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu J, Zhang C, Feng Z. Tumor suppressor p53 and its gain-of-function mutants in cancer. Acta Biochim Biophys Sin Shanghai. 2014;46:170–179. doi: 10.1093/abbs/gmt144.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/abbs/gmt144</ArticleId>
            <ArticleId IdType="pmc">PMC3932832</ArticleId>
            <ArticleId IdType="pubmed">24374774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muller PA, Vousden KH, Norman JC. p53 and its mutants in tumor cell migration and invasion. J Cell Biol. 2011;192:209–218. doi: 10.1083/jcb.201009059.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1083/jcb.201009059</ArticleId>
            <ArticleId IdType="pmc">PMC3172183</ArticleId>
            <ArticleId IdType="pubmed">21263025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hinestrosa JP, Kurzrock R, Lewis JM, Schork NJ, Schroeder G, Kamat AM, Lowy AM, Eskander RN, Perrera O, Searson D, et al.  Early-stage multi-cancer detection using an extracellular vesicle protein-based blood test. Commun Med. 2022;2:29. doi: 10.1038/s43856-022-00088-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s43856-022-00088-6</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park MH, Reategui E, Li W, Tessier SN, Wong KH, Jensen AE, Thapar V, Ting D, Toner M, Stott SL, Hammond PT. Enhanced isolation and release of circulating tumor cells using nanoparticle binding and ligand exchange in a microfluidic Chip. J Am Chem Soc. 2017;139:2741–2749. doi: 10.1021/jacs.6b12236.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/jacs.6b12236</ArticleId>
            <ArticleId IdType="pmc">PMC5506378</ArticleId>
            <ArticleId IdType="pubmed">28133963</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
